For instance, pazopanib acts as an anti-angiogenic through the inhibition of VEGFR, PDGFR, and c-Kit in human renal carcinoma, soft tissue sarcoma, and breast cancer in combination with the anti-HER-2 lapatinib (163). This evidence concerns the gene ERBB2 and breast carcinoma.